Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa

被引：17
|
作者：
Siniscalchi, Antonio
Gallelli, Luca
Mercuri, Nicola B.
Ibbadu, Guido Ferreri
De Sarro, Giovambattista
机构：
[1] Mater Domini Univ Hosp, Fac Med & Surg Univ Magna Grecia, Dept Expt & Clin Med, Clin Pharmacol Unit, Catanzaro, Italy
[2] Annunziata Hosp, Dept Neurosci, Div Neurol, Cosenza, Italy
[3] Univ Roma Tor Vergata, IRCCS S Lucia, Rome, Italy
[4] Univ Roma Tor Vergata, Dept Neurol, Rome, Italy
来源：
NUTRITIONAL NEUROSCIENCE | 2006年 / 9卷 / 1-2期
关键词：
homocysteine; Parkinson's disease patients; vitamin; coffee; smoke; behaviours;
D O I：
10.1080/10284150600583446
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Many papers documented that Parkinson's disease (PD) patients treated with levodopa (L-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that L-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during L-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.
引用
收藏
页码：11 / 16
页数：6
相关论文
共 50 条
  • [31] Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in alzheimer’s disease patients and in Parkinson’s disease patients
    S. Genedani
    G. Rasio
    P. Cortelli
    F. Antonelli
    D. Guidolin
    M. Galantucci
    K. Fuxe
    L. F. Agnati
    [J]. Neurotoxicity Research, 2004, 6 : 327 - 332
  • [32] Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease
    O'Suilleabhain, PE
    Bottiglieri, T
    Dewey, RB
    Sharma, S
    Diaz-Arrastia, R
    [J]. MOVEMENT DISORDERS, 2004, 19 (12) : 1403 - 1408
  • [33] Elevated plasma levels of homocysteine in Parkinson's disease
    Kuhn, W
    Roebroek, R
    Blom, H
    van Oppenraaij, D
    Przuntek, H
    Kretschmer, A
    Büttner, T
    Woitalla, D
    Müller, T
    [J]. EUROPEAN NEUROLOGY, 1998, 40 (04) : 225 - 227
  • [34] Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfuntions: A causal link?
    Zoccolella, S
    Diroma, C
    Fraddosio, A
    Mastronardi, R
    Russo, I
    Lamberti, S
    [J]. MOVEMENT DISORDERS, 2005, 20 : S119 - S119
  • [35] Plasma levodopa level treated with levodopa in combination with carbidopa or benserazide in Parkinson's disease
    Nomoto, M
    Nagai, M
    Yabe, H
    Nakatsuka, A
    Moritoyo, T
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 118P - 118P
  • [36] Effect of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study
    Anamnart, Chumpol
    Kitjarak, Ram
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 319 - 319
  • [37] Mortality in Parkinson's disease patients treated with levodopa
    Morgan, JC
    Currie, LJ
    Bennett, JP
    Harrison, MB
    Trugman, JM
    Wooten, GF
    [J]. NEUROLOGY, 2002, 58 (07) : A109 - A109
  • [38] Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study
    Anamnart, Chumpol
    Kitjarak, Ram
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2021, 88 : 226 - 231
  • [39] Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels
    Kulisevsky, J
    Avila, A
    Barbanoj, M
    Antonijoan, R
    Berthier, ML
    Gironell, A
    [J]. BRAIN, 1996, 119 : 2121 - 2132
  • [40] Plasma homocysteine levels and mortality in patients with coronary artery disease
    Farhadi, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (22): : 1632 - 1632
12345